Cutaneous mosaicism: Right before our eyes

Journal of Clinical Investigation

Volumn 117, Issue 5, 2007, Pages 1216-1219

  Frank, Jorge ^a   Happle, Rudolf ^b  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN; COLLAGEN TYPE 17A1; FIBROBLAST GROWTH FACTOR RECEPTOR 3; LAMININ BETA3; MEMBRANE PROTEIN; RETROVIRUS VECTOR; UNCLASSIFIED DRUG;

AUTOTRANSPLANTATION; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE COURSE; DISEASE SEVERITY; EPIDERMOLYSIS BULLOSA; GENE MUTATION; HAILEY HAILEY DISEASE; HETEROZYGOSITY LOSS; HUMAN; LESCH NYHAN SYNDROME; MOSAICISM; NONHUMAN; NOTE; OMENN SYNDROME; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; REVERTANT; RNA INTERFERENCE; RNA SPLICING; SKIN GRAFT; SKIN TUMOR; SOMATIC MUTATION; TYROSINEMIA; VIRAL GENE THERAPY;

ANIMALS; EPIDERMOLYSIS BULLOSA; GENE THERAPY; HUMANS; MOSAICISM; REMISSION, SPONTANEOUS;

EID: 34248165911     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI32111     Document Type: Note

References (26)

1. McKusick, V.A. 1973. Genetics and dermatology or if I were to rewrite Cockayne's Inherited abnormalities of the skin. J. Invest. Dermatol. 60:343-359.
2. McGrath, J.A. 2004. Translational benefits from research on rare genodermatoses. Australas. J. Dermatol. 45:89-93.
3. Irvine, A.D., and McLean, W.H. 2003. The molecular genetics of the genodermatoses: progress to date and future directions. Br. J. Dermatol. 148:1-13.
4. Happle, R. 1995. What is a nevus? A proposed definition of a common medical term. Dermatology. 191:1-5.
5. Happle, R. 2006. X-chromosome inactivation: role in skin disease expression. Acta Paediatr. Suppl. 95:16-23.
6. Yochem, J., Sundaram, M., and Bucer, E.A. 2000. Mosaic analysis in Caenorhabditis elegans. Methods Mol. Biol. 135:447-462.
7. Blair, S.S. 2003. Genetic mosaic techniques for studying Drosophila development. Development. 130:5065-5072.
8. Rossant, J., and Spence, A. 1998. Chimeras and mosaics in mouse mutant analysis. Trends Genet. 14:358-363.
9. Carmany-Rampey, A., and Moens, C.B. 2006. Modern mosaic analysis in the zebrafish. Methods. 39:228-238.
10. Happle, R. 2002. Dohi Memorial Lecture: new aspects of cutaneous mosaicism. J. Dermatol. 29:681-692.
11. Poblete-Gutiérrez, P., et al. 2004. Allelic loss underlies type 2 segmental Hailey-Hailey disease, providing molecular confirmation of a novel genetic concept. J. Clin. Invest. 114:1467-1474. doi:10.1172/JCI200421791.
12. Happle, R. 1996. Segmental forms of autosomal dominant skin disorders: different types of severity reflect different states of zygosity. Am. J. Med. Genet. 66:241-242.
13. Happle, R., and König, A. 1999. Dominant traits may give rise to paired patches of either excessive or absent involvement. Am. J. Med. Genet. 84:176-177.
14. Pasmooij, A.M.G., Pas, H.H., Bolling, M.C., and Jonkman, M.F. 2007. Revertant mosaicism in junctional epidermolysis bullosa due to multiple correcting second-site mutations in LAMB3. J. Clin. Invest. 117:1240-1248. doi:10.1172/JCI30465.
15. Hafner, C., et al. 2006. Mosaicism of activating FGFR3 mutations in human skin causes epidermal nevi. J. Clin. Invest. 116:2201-2207. doi:10.1172/JCI28163.
16. Meyer, M., and Wagner, E. 2006. Recent developments in the application of plasmid DNA-based vectors and small interfering RNA therapeutics for cancer. Hum. Gene Ther. 17:1062-1076.
17. Xia, X., Zhou, H., Huang, Y., and Xu, Z. 2006. Allele-specific RNAi selectively silences mutant SOD1 and achieves significant therapeutic benefit in vivo. Neurobiol. Dis. 23:578-586.
18. Yang, T.P., Stout, J.T., Patel, P.I., Alsford, R.L., and Caskey, C.T. 1988. Spontaneous reversion of novel Lesch-Nyhan mutation by HPRT gene rearrangement. Somat. Cell Mol. Genet. 14:293-303.
19. Jonkman, M.F. 1999. Revertant mosaicism in human genetic disorders. Am. J. Med. Genet. 85:361-364.
20. Bittar, M., and Happle, R. 2005. Revertant mosaicism and retrotransposons: another explanation of "natural gene therapy". Am. J. Med. Genet. A. 137:222.
21. Pizzuti, A., Pieretti, M., Fenwick, R.G., Gibba, R.A., and Caskey, C.T. 1992. A transposon-like element in the deletion-prone region of the dystrophin gene. Genomics. 13:594-600.
22. Thanh, L.T., Nguyen, T.M., Helliwell, T.R., and Morris, G.E. 1995. Characterization of revertant muscle fibers in Duchenne muscular dystrophy, using exon-specific monoclonal antibodies against dystrophin. Am. J. Hum. Genet. 56:725-731.
23. Jonkman, M.F., et al. 1997. Revertant mosaicism in epidermolysis bullosa caused by mitotic gene conversion. Cell. 88:543-551.
24. Bliksrud, Y.T., Brodtkorb, E., Andresen, P.A., van den Berg, I.E.T., and Kvittingen, E.A. 2005. Tyrosinaemia type I - de novo mutation in liver tissue suppressing an inborn splicing defect. J. Mol. Med. 83:406-410.
25. Wada, T., et al. 2005. Oligoclonal expansion of T lymphocytes with multiple second-site mutations leads to Omenn syndrome in a patient with RAG1-deficient severe combined immunodeficiency. Blood. 106:2099-2101.
26. Mavilio, F., et al. 2007. Correction of junctional epidermolysis bullosa by transplantation of genetically modified epidermal stem cells. Nat. Med. 12:1397-1402.